Medtronic Activa Approvable With Conditions; Data Show Dyskinesia Drop Off
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's Activa Parkinson's control therapy system should be indicated for treatment only of "advanced levadopa (L-dopa) responsive" Parkinson's patients, FDA's Neurological Devices Panel recommended at a March 31 meeting in Rockville, Maryland.
You may also be interested in...
Medtronic Activa Postmarket Study On Parkinson’s Will Begin By Summer
Medtronic's 230-patient, three-year post-approval study of its Activa Parkinson's disease neurostimulation therapy will begin enrollment by this summer
Medtronic Activa Postmarket Study On Parkinson’s Will Begin By Summer
Medtronic's 230-patient, three-year post-approval study of its Activa Parkinson's disease neurostimulation therapy will begin enrollment by this summer
Medtronic Garners Bilateral Activa Medicare Reimbursement In 33 States
Medtronic Neurological President Scott Ward acknowledges that current off-label use of the company's Activa deep brain stimulation device for the bilateral treatment of Parkinson's tremor may dampen sales expectations once FDA approves the indication.